Risk factor
Considerable default risk
Profitability factor
Very poor margins and returns
About
Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such as oocyte retrieval needles, sperm processing solutions, specialized in vitro fertilization media and oils, and micromanipulation pipettes. The company also provides general labware, incubators, cryopreservation products, and systems for preimplantation genetic testing. Furthermore, Vitrolife delivers advanced equipment, including the EmbryoScope and Primo Vision time-lapse systems, along with dedicated dishes and evaluation software for these platforms. Their technology portfolio extends to Octax laser and imaging systems, as well as environmental monitoring solutions like log and guard systems and wireless sensors. With its headquarters located in Gothenburg, Sweden, Vitrolife maintains a significant international presence, operating across Europe, the Middle East, and Africa; Asia; Japan and the Pacific; and both North and South America. Founded in 1994, the company was initially known as Scandinavian IVF Science before officially changing its name to Vitrolife AB (publ) in 1998.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, reasonably priced
Target Price
The average target price of VITR.ST is 131 and suggests 53.5% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in